KRAS Mutation-Related Tumors
14
4
5
4
Key Insights
Highlights
Success Rate
57% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 87/100
21.4%
3 terminated out of 14 trials
57.1%
-29.4% vs benchmark
0%
0 trials in Phase 3/4
50%
2 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (14)
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
NEROFE and Doxorubicin in KRAS-mutated ST2-positive Solid Tumors
Real-Time Monitoring of Symptoms in Lung Cancer Patients Receiving Oral Targeted Therapies
Trial of Single Protein Encapsulated Doxorubicin, SPEDOX-6 in Advanced Malignancies
A Study of RGX-202-01 (Ompenaclid) as Combination Therapy in RAS Mutant Advanced Colorectal Cancer
Binimetinib and Hydroxychloroquine in Patients With Advanced KRAS Mutant Non-Small Cell Lung Cancer
Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancreatic Cancer, and Colorectal Cancer
Combination Therapy of RMC-4630 and LY3214996 in Metastatic KRAS Mutant Cancers
Trametinib Plus Anlotinib Combined With Tislelizumab in KRAS-mutant NSCLC
A Study of Repotrectinib in Combination With Other Anticancer Therapies for the Treatment of Subjects With KRAS-Mutant Solid Tumors
A Study of ZG2001 in Participants With KRAS Mutated Advanced Solid Tumours
Evaluation of the Response to Tyrosine Kinase Inhibitors in Localized Non-small Cell Lung Cancer (NSCLC) Patients With EGFR Mutation in a Patient-derived Organoid Model
Patogenic Mutation in 5 Genes
CIrculating Tumor DNA for Monitoring Response to First Line Chemotherapy in Unresectable PANcreatic Cancer